Objective:

To discuss Dr. Terry Kim's roles at Alcon and the impact of new ophthalmic technologies, including the Unity Vitreoretinal Cataract System and Voyager DSLT laser therapy.

Approach:

Key Findings:

• Unity systems received FDA 510(k) clearance in 2024, enhancing cataract surgery efficiency and potentially improving patient outcomes.
• Voyager DSLT aims to simplify glaucoma laser therapy, improving patient experience by allowing patients to remain seated during the procedure.
• New gas delivery systems streamline procedures and enhance accuracy in ophthalmic surgeries, addressing previous inefficiencies.

Interpretation:

Dr. Kim's insights highlight the importance of integrating clinical experience into product development to address unmet needs in eye care.

Limitations:

• The article does not provide quantitative data on the effectiveness of the new systems, limiting the assessment of their impact.
• Feedback from user evaluations is mentioned but lacks specific examples or details.

Conclusion:

Dr. Kim's leadership at Alcon aims to bridge clinical practice with innovative solutions in ophthalmology, drawing on his extensive clinical experience.

Source

Based on findings from:

Industry Insider: Alcon’s Dr. Terry Kim

Ophthalmology Management, 2025.

https://www.ophthalmologymanagement.com/issues/2025/march/industry-insider

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.